FDA accepts UroGen Pharma’s NDA for bladder‑cancer therapy UGN‑103

UroGen Pharma announced that the U.S. Food and Drug Administration has accepted its New Drug Application for UGN‑103, an intravesical mitomycin formulation for recurrent low‑grade intermediate‑risk non‑muscle‑invasive bladder cancer. The agency set a PDUFA target action date of June 14 2027. Phase 3 UTOPIA trial data supporting the filing showed a 77.8% complete response rate at three months and a 94.5% probability of remaining event‑free at six months among responders.

The acceptance moves the product toward a potential approval by mid‑2027, which could expand UroGen’s bladder‑cancer franchise and drive future revenue. H.C. Wainwright reiterated a Buy rating with a $75 price target, implying significant upside from the current share price.

  • 1The FDA accepted the NDA for UGN‑103 and assigned a PDUFA target action date of June 14 2027.
  • 2Phase 3 UTOPIA trial data showed a 77.8% complete response rate at three months.
  • 3Among responders, the Kaplan‑Meier estimated probability of remaining event‑free at six months was 94.5%.
  • 4UroGen shares were down 2.05% at $33.85 after the announcement.
  • 5UroGen shares rose 0.69% to $34.80 in pre‑market trading following the news.
  • 6H.C. Wainwright reiterated a Buy rating and a $75 price target for URGN.

Sources